Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma

Table 3

Response rates of BEZ235-treated tumors.

	Tumor response rate
	Complete	Partial	All  responders
BEZ235	1/9	2/9	3/9 (33%)
BEZ235+Dox	5/10	3/10	8/10 (80%)
Total	6/19	5/19	11/19 (58%)